These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24858874)

  • 1. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program.
    Roose RJ; Cockerham-Colas L; Soloway I; Batchelder A; Litwin AH
    J Health Care Poor Underserved; 2014 May; 25(2):652-62. PubMed ID: 24858874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating HCV services for drug users: a model to improve engagement and outcomes.
    Sylvestre DL; Zweben JE
    Int J Drug Policy; 2007 Oct; 18(5):406-10. PubMed ID: 17854729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceived benefits of the hepatitis C peer educators: a qualitative investigation.
    Batchelder AW; Cockerham-Colas L; Peyser D; Reynoso SP; Soloway I; Litwin AH
    Harm Reduct J; 2017 Sep; 14(1):67. PubMed ID: 28962652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care.
    Marinho RT; Costa A; Pires T; Raposo H; Vasconcelos C; Polónia C; Borges J; Soares M; Vilar G; Nogueira AM;
    BMC Infect Dis; 2016 Oct; 16(1):565. PubMed ID: 27733137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection.
    Crawford S; Bath N
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S75-9. PubMed ID: 23884070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users.
    Coupland H; Day C; Levy MT; Maher L
    Health Promot J Austr; 2009 Dec; 20(3):234-40. PubMed ID: 19951245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services.
    Strauss SM; Astone-Twerell J; Munoz-Plaza CE; Des Jarlais DC; Gwadz M; Hagan H; Osborne A; Rosenblum A
    BMC Health Serv Res; 2007 Mar; 7():39. PubMed ID: 17346346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions of drug users regarding hepatitis C screening and care: a qualitative study.
    Jordan AE; Masson CL; Mateu-Gelabert P; McKnight C; Pepper N; Bouche K; Guzman L; Kletter E; Seewald RM; Des-Jarlais DC; Sorensen JL; Perlman DC
    Harm Reduct J; 2013 Jun; 10():10. PubMed ID: 23786800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study.
    Barocas JA; Brennan MB; Hull SJ; Stokes S; Fangman JJ; Westergaard RP
    Harm Reduct J; 2014 Jan; 11():1. PubMed ID: 24422784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment.
    Henderson C; Madden A; Kelsall J
    Int J Drug Policy; 2017 Dec; 50():111-115. PubMed ID: 28927831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia.
    Kikvidze T; Luhmann N; Avril E; Butsashvili M; Labartkava K; Etienne A; Le Pluart D; Inaridze I; Gamezardashvili A; Kharshiladze D; Bouscaillou J
    Int J Drug Policy; 2018 Feb; 52():16-19. PubMed ID: 29227878
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review.
    Socías ME; Karamouzian M; Parent S; Barletta J; Bird K; Ti L
    Int J Drug Policy; 2019 Oct; 72():146-159. PubMed ID: 31147142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peer involvement and cross-sector efforts in establishing integrated treatment of hepatitis C virus infection for people with substance use disorders: experiences from Norway.
    Lygren OJ; Bjørnestad R; Løberg EM; Bonnier ML; Buljovcic VB; Johansson KA; Fadnes LT;
    Subst Abuse Treat Prev Policy; 2019 Dec; 14(1):58. PubMed ID: 31864396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion.
    Hong BA; North CS; Pollio DE; Abbacchi A; Debold C; Adewuyi SA; Lisker-Melman M
    J Clin Psychol Med Settings; 2011 Mar; 18(1):99-107. PubMed ID: 21336614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment.
    Roncero C; Littlewood R; Vega P; Martinez-Raga J; Torrens M
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):629-633. PubMed ID: 28230562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
    Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
    Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration.
    Swan D; Long J; Carr O; Flanagan J; Irish H; Keating S; Keaveney M; Lambert J; McCormick PA; McKiernan S; Moloney J; Perry N; Cullen W
    AIDS Patient Care STDS; 2010 Dec; 24(12):753-62. PubMed ID: 21138381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing chronic hepatitis C acquired through intravenous drug use.
    Jowett SL; Agarwal K; Smith BC; Craig W; Hewett M; Bassendine DR; Gilvarry E; Burt AD; Bassendine MF
    QJM; 2001 Mar; 94(3):153-8. PubMed ID: 11259690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.